NCT05848219View on ClinicalTrials.gov

Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib

TerminatedOBSERVATIONAL
Enrollment

543

Participants

Timeline

Start Date

October 16, 2021

Primary Completion Date

April 27, 2022

Study Completion Date

April 27, 2022

Conditions
Metastatic Melanoma
Trial Locations (1)

07936

Novartis Investigational Site, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY